• Atossa Therapeutics, Breast Health

Dr. Steven Quay Discusses Atossa Therapeutics’ Breakthrough in Breast Cancer Treatment on Market Movers

In a recent appearance on Market Movers: The Opening Bell from FINTECH.TV, Dr. Steven Quay, CEO of Atossa Therapeutics, shared key updates on the company’s progress toward transforming breast cancer treatment.

Dr. Quay explained how Atossa’s lead therapy, V-endoxifen, isolates the most effective component of tamoxifen to deliver targeted results with fewer side effects. Over 700 women have participated in clinical trials so far, showing a promising safety profile.

With guidance from the FDA expected by year’s end, Atossa plans to advance its 505(b)(2) regulatory pathway—a process that leverages existing tamoxifen data to accelerate approval.

Dr. Quay also highlighted Atossa’s strong financial position, noting $58 million in cash, no debt, and a disciplined approach to growth. He emphasized the company’s commitment to helping the 1.7 million women currently taking tamoxifen or aromatase inhibitors by providing a safer, next-generation alternative.

Watch the full Market Movers interview on FINTECH.TV and learn more at atossatherapeutics.com.

  • Tags: Atossa Therapeutics, biotechnology, Breast Cancer Awareness, Breast cancer research, Dr. Steven Quay, FDA approval, FINTECH.TV, Market Movers, NASDAQ ATOS, oncology, V-endoxifen, Women’s Health

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

Embracing Breast Cancer Awareness with Dr. Steven Quay

October 22, 2025

Dr. Steven Quay joins Tony Mantor’s Why Not Me? podcast to discuss breast cancer prevention, early detection, and hope for women worldwide during Breast Cancer Awareness Month.

Can Breast Cancer Be Prevented? Dr. Steven Quay Featured on CEO Talks

September 20, 2025

Florida Vows to End Childhood Vaccine Mandates: Dr. Steven Quay Explains the Impact

September 7, 2025